Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of “Buy” by Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been assigned an average recommendation of “Buy” from the ten brokerages that are covering the firm, MarketBeat reports. Eight equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $52.14.

A number of research analysts have recently issued reports on the stock. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Guggenheim reissued a “buy” rating and issued a $84.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Wedbush reissued an “outperform” rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, TD Cowen started coverage on Dianthus Therapeutics in a report on Friday, December 20th. They issued a “buy” rating on the stock.

Institutional Trading of Dianthus Therapeutics

Several hedge funds have recently added to or reduced their stakes in DNTH. Quest Partners LLC raised its stake in Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after acquiring an additional 1,124 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Dianthus Therapeutics by 142.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock valued at $4,543,000 after purchasing an additional 97,362 shares in the last quarter. MetLife Investment Management LLC raised its stake in shares of Dianthus Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 13,939 shares of the company’s stock valued at $382,000 after purchasing an additional 7,854 shares in the last quarter. Walleye Capital LLC bought a new stake in shares of Dianthus Therapeutics during the 3rd quarter worth about $821,000. Finally, Braidwell LP raised its position in shares of Dianthus Therapeutics by 34.6% during the 3rd quarter. Braidwell LP now owns 493,687 shares of the company’s stock worth $13,517,000 after buying an additional 126,836 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Down 5.6 %

NASDAQ:DNTH opened at $20.74 on Wednesday. The business’s 50 day moving average is $22.34 and its two-hundred day moving average is $24.70. Dianthus Therapeutics has a 52 week low of $18.13 and a 52 week high of $33.77. The company has a market cap of $613.84 million, a PE ratio of -8.30 and a beta of 1.82.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $1.33 million for the quarter, compared to analysts’ expectations of $1.40 million. As a group, sell-side analysts expect that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.